Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors

PURPOSE: To clinically evaluate the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in solid cancer patients. EXPERIMENTAL DESIGN: Preclinical modeling in syngeneic tumor models was used to assess the relationship between dose, pharmacokinetics, receptor occupancy, and efficacy, as well as pharmacodynamic biomarkers measured in peripheral blood and tumors. These findings informed dosing and analyses in a first-in-human phase 1 dose-escalation trial in patients with solid cancers. RESULTS: BI-1808 was safe and well-tolerated, showed expected pharmacokinetics, and achieved full receptor occupancy throughout the three-week dosing interval. Tumor regression was observed in two patients, one with non-small cell lung cancer and one with gastrointestinal sarcoma. Stable disease was observed in 6 of 21 evaluable patients. Tumor regression was preceded by increases in circulating CX3CR1+CD8+ T cells and tumor-infiltrating CD8+ T cells, consistent with activation of antitumor immunity. Pharmacodynamic analyses were consistent with the preclinically characterized mechanism of action, including dose-dependent reduction of regulatory T cells, monocyte activation, and serum cytokines indicating myeloid reprogramming, tertiary lymphoid structure formation, and CD8+ T-cell activation. CONCLUSIONS: These early clinical findings support further development of ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibodies as a safe and mechanistically distinct cancer immunotherapy strategy. The excellent safety profile of BI-1808 makes it well-suited for combination with other immunotherapies, targeted agents, chemotherapeutics, cell therapies, and ADCs.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-10-15
DOI
https://doi.org/10.1158/1078-0432.ccr-26-2049
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors

Andrés McAllister, Jeffrey Yachnin, Marie Borggren, Monika Semmrich et al.
Clinical Cancer Research
Cancer Immunotherapy and Biomarkers
article

Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors

Andrés McAllister, Jeffrey Yachnin, Marie Borggren, Monika Semmrich, Susanne Gertsson, Björn Frendéus, Marica Vaapil, Mathilda Kovacek, Harriet S. Walter, Alexandra Gabriela Ferreira, Kirstie L.S. Cleary, Kristoffer Staal Rohrberg, Petra Holmkvist, Robert J. Oldham, Ingrid Teige, Benjamin L. Duell, Johan Erik Wallin, Sean H. Lim, Ana Carneiro, Carolin Svensson, Ingrid Karlsson, Rikke Løvendahl Eefsen, Therese Blidberg, Stephen A. Beers, Anette Sundstedt, Zsuzsanna Pápai, Mark Steven Cragg, Niyaz Yoosuf, István Láng, Linda Mårtensson, Jan Nilsson, Danijela Lindahl
article en

Abstract

PURPOSE: To clinically evaluate the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in solid cancer patients. EXPERIMENTAL DESIGN: Preclinical modeling in syngeneic tumor models was used to assess the relationship between dose, pharmacokinetics, receptor occupancy, and efficacy, as well as pharmacodynamic biomarkers measured in peripheral blood and tumors. These findings informed dosing and analyses in a first-in-human phase 1 dose-escalation trial in patients with solid cancers. RESULTS: BI-1808 was safe and well-tolerated, showed expected pharmacokinetics, and achieved full receptor occupancy throughout the three-week dosing interval. Tumor regression was observed in two patients, one with non-small cell lung cancer and one with gastrointestinal sarcoma. Stable disease was observed in 6 of 21 evaluable patients. Tumor regression was preceded by increases in circulating CX3CR1+CD8+ T cells and tumor-infiltrating CD8+ T cells, consistent with activation of antitumor immunity. Pharmacodynamic analyses were consistent with the preclinically characterized mechanism of action, including dose-dependent reduction of regulatory T cells, monocyte activation, and serum cytokines indicating myeloid reprogramming, tertiary lymphoid structure formation, and CD8+ T-cell activation. CONCLUSIONS: These early clinical findings support further development of ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibodies as a safe and mechanistically distinct cancer immunotherapy strategy. The excellent safety profile of BI-1808 makes it well-suited for combination with other immunotherapies, targeted agents, chemotherapeutics, cell therapies, and ADCs.

Clinical Cancer Research
Scania (Sweden) (SE), Karolinska University Hospital (SE), University of Leicester (GB), Lund University (SE), Herlev Hospital (DK), Rigshospitalet (DK), BM Központi Kórház (HU), BioInvent (Sweden) (SE), University of Southampton (GB)
Good health and well-being
Openalex Percentile: Top 17%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.